Hippocampal Malrotation is Associated with Chromosome 22q11.2 Microdeletion

Danielle M. Andrade, Timo Krings, Eva W.C. Chow, Tim-Rasmus Kiehl, Anne S. Bassett

ABSTRACT: Background: Patients with chromosome 22q11.2 deletion syndrome (22q11DS) are at a seven fold increased risk of developing seizures. However, only a fraction of these patients exhibit structural abnormalities such as polymicrogyria (PMG) and periventricular nodular heterotopia (PNH) that are known to cause seizures and to be associated with 22q11DS. In this study we used a dedicated seizure imaging protocol to look for additional structural abnormalities in these individuals that may explain the elevated risk of seizure disorder in this patient group. Methods: Nineteen consecutive adult subjects with 22q11DS underwent a 3 Tesla MRI with a dedicated high-resolution seizure protocol. Neurological exam was performed in all patients. Genome-wide analysis excluded the presence of other known pathogenic microdeletions or duplications. Results: Structural abnormalities were found in 11 of 14 subjects with sufficient image quality. These included three patients with PNH, one of whom had associated PMG. In addition, there was a surprisingly high prevalence of unilateral hippocampal malrotation (HIMAL), observed in 9 of 14 cases (64%). EEG findings showed interictal epileptiform discharges with focal distribution in four patients and generalized discharges in one patient. Conclusion: The results suggest that, in addition to other known structural abnormalities, 22q11DS is associated with HIMAL. It has been suggested that this developmental abnormality of the hippocampus may predispose or otherwise contribute to epileptogenesis. However in this study we observed HIMAL in a large proportion of patients, with and without epilepsy. Therefore, other as yet unknown factors may contribute to the high prevalence of epilepsy in this population.

RÉSUMÉ: La malrotation de l’hippocampe est associée à une microdélétion 22q11.2. Contexte: Les patients atteints du syndrome associé à la délétion située sur le chromosome 22q11.2 (22q11DS) ont un risque 7 fois supérieur de présenter des crises d’épilepsie. Cependant, seulement un petit nombre de ces patients présentent des anomalies structurales telles la polymicrogyrie (PMG) et l’hétéropie nodulaire pérventriculaire (PNH) qui sont des causes connues de crises convulsives et sont associées à 22q11DS. Dans cette étude, nous avons eu recours à un protocole d’imagerie spécifique pour mettre en évidence les crises convulsives afin de tenter de mettre en évidence d’autres anomalies structurales qui pourraient expliquer le risque élevé de désordre convulsif chez ce groupe de patients. Méthode: Dix-neuf sujets adultes consécutifs porteurs de 22q11DS ont subi une IRM 3 Tesla utilisant un protocole spécifique à haute résolution pour les crises convulsives. Un examen neurologique a été effectué chez tous les patients. Une analyse génomique a exclu la présence d’autres microdélétions ou duplications pathogènes. Résultats: Des anomalies structurales ont été détectées chez 11 des 14 sujets dont la qualité de l’imagerie était adéquate. Trois de ces patients étaient porteurs de PNH dont un avait également une PMG. De plus, à notre grande surprise, la prévalence d’une malrotation unilatérale de l’hippocampe (MALHI) était élevée, soit chez 9 des 14 patients (64%). Les constatations faites à l’EEG incluent des décharges épileptiformes interictales à distribution focale chez 4 patients et des décharges généralisées chez un patient. Conclusion: Selon ces résultats, 22q11DS est associé à une MALHI, en plus des autres anomalies structurales connues. Il a été proposé que cette anomalie du développement de l’hippocampe puisse prédisposer, ou à tout le moins contribuer, à l’épileptogénèse. Cependant, dans cette étude nous avons observé une MALHI chez une grande proportion de patients avec ou sans épilepsie. D’autres facteurs encore inconnus pourraient donc contribuer à la prévalence élevée d’épilepsie dans cette population de patients.


Microdeletion at chromosome 22q11.2 is the most common pathogenic copy number variation (CNV) in humans, affecting 1/4000 live births1,2. Chromosome 22 has a region particularly susceptible to chromosomal rearrangements due to the presence of several areas of low copy repeats. Hemizygous deletions in this 22q11.2 region, most commonly involving 3Mb1,4 and encompassing more than 45 genes5, are responsible for 22q11.2 deletion syndrome (22q11DS). Patients with 22q11DS are clinically very complex with multisystem abnormalities. There are over 40 common clinical features6. Typical features include learning disabilities, subtle dysmorphic faces, velopharyngeal insufficiency, and congenital heart disease. Hypocalcemia due to parathyroid dysfunction are also very common7,8. Schizophrenia develops in up to 25% of patients9,10.

Epilepsy is 7 times more common in patients with 22q11DS than the general population11,12. Non-hypocalcemic seizures in 22q11DS patients can have generalized or partial (i.e. focal) onset. According to Kao et al, partial onset seizures affect 5.5%
of all patients with 22q11DS. Known potential causes of partial onset seizures in this group of patients include rare case reports of polymicrogyria (PMG)\textsuperscript{13}, periventricular nodular heterotopia (PNH)\textsuperscript{14}, or hippocampal atrophy (HA)\textsuperscript{15}. However, the prevalence of these abnormalities in the 22q11DS population is low, accounting for, at most, 25% of all cases of partial onset epilepsy\textsuperscript{11,12}. Since there is a discrepancy between the prevalence of partial onset epilepsy and the prevalence of known causal structural abnormalities, the aim of this study was to evaluate a series of subjects with 22q11DS, using high resolution magnetic resonance imaging (MRI) and electroencephalography (EEG) to specifically search for additional findings to explain this difference.

**PATIENTS AND METHODS**

Patients: Nineteen adult patients with 22q11DS consecutively referred between 2009-2011 from an adult cohort enriched for neuropsychiatric disorders\textsuperscript{4} comprised the sample for this study. Inclusion criteria: absence of other pathogenic CNVs. Exclusion criteria: seizures associated with stroke or hypocalcemia. Patients without previous history of seizures were included.

Epilepsy history and assessment was conducted by an experienced epileptologist (DA). Diagnosis of epilepsy and seizure types was made according to the classification of the International League Against Epilepsy (www.ilae.org). Electroencephalogram (EEG) studies: Patients were subjected to prolonged digital EEG recordings lasting between one and seven days. Overnight recordings were obtained either through admission to an Epilepsy Monitoring Unit or through ambulatory EEG. Digital EEG recordings were performed using the international 10-20 system in XLTEK recording equipment.

Genetic studies: 22q11.2 microdeletion was confirmed by FISH analysis using standard probes in all patients\textsuperscript{4,16}. All participants also had genome-wide microarray data available to exclude the presence of other pathogenic CNVs\textsuperscript{4}.

Imaging: Patients were scanned on a 3 Tesla magnetic resonance imaging (MRI) system using an eight-channel head coil. We used a dedicated seizure scanning protocol including axial and coronal high resolution T1 IR (TE/TR/TI: 42/6500/170ms; 3mm slice thickness, 512x512 Matrix) and T2 FLAIR (TE/TR/IR/: 136/8650/2250ms, 4mm slice thickness, 384x224 Matrix) sequences. Coronal sequences were angulated perpendicular to the hippocampi and caution was taken to

**Table: General characteristics of 19 adult patients with 22q11.2 deletion syndrome**

<table>
<thead>
<tr>
<th>Case #</th>
<th>Sex</th>
<th>Age (y)</th>
<th>disability</th>
<th>SZ</th>
<th>neuropsych</th>
<th>Seizure type</th>
<th>EEG findings</th>
<th>MRI findings</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Patients with epilepsy</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>F</td>
<td>23</td>
<td>Borderline</td>
<td>✓ ADHD</td>
<td>GTCs and MS</td>
<td>3-4Hz G-PWS</td>
<td>N ✓</td>
<td>✓</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>58</td>
<td>Mild</td>
<td>O</td>
<td>2° GTCs</td>
<td>BT</td>
<td>S</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>36</td>
<td>Severe</td>
<td>✓ OCD</td>
<td>CPS and 2° GTCs</td>
<td>RT, LFC</td>
<td>S</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>19</td>
<td>Mild</td>
<td>✓ OCD</td>
<td>CPS and 2° GTCs</td>
<td>G</td>
<td>S ✓</td>
<td>✓</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>34</td>
<td>Mild</td>
<td>✓ CPS and 2° GTCs</td>
<td>G</td>
<td>N ✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>43</td>
<td>Borderline</td>
<td>✓ CPS</td>
<td>BT</td>
<td>BT N ✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>24</td>
<td>Mild</td>
<td>✓ CPS</td>
<td>BF</td>
<td>S</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Patients without epilepsy</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>22</td>
<td>Mild</td>
<td>✓ MD</td>
<td>LFC</td>
<td>BF</td>
<td>N ✓</td>
<td>✓</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>40</td>
<td>Borderline</td>
<td>✓</td>
<td>BPQ</td>
<td>N ✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>20</td>
<td>Borderline</td>
<td>✓</td>
<td>BT</td>
<td>N ✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>19</td>
<td>Borderline</td>
<td>✓</td>
<td></td>
<td>N ✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>30</td>
<td>Mild</td>
<td>✓</td>
<td></td>
<td>N ✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>34</td>
<td>Mild</td>
<td>✓</td>
<td>G</td>
<td>N ✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>F</td>
<td>20</td>
<td>Mild</td>
<td>✓</td>
<td>MD</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>37</td>
<td>Borderline</td>
<td>✓ MD, GAD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>F</td>
<td>26</td>
<td>Borderline</td>
<td>✓ MD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>M</td>
<td>21</td>
<td>Normal</td>
<td>✓ ASD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>M</td>
<td>37</td>
<td>Borderline</td>
<td>✓ OCD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>M</td>
<td>37</td>
<td>Borderline</td>
<td>✓ OCD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

All patients with schizophrenia (SZ) or other psychotic illnesses were receiving antipsychotic medications. Patients with major depression and/or anxiety disorders were receiving antidepressant/anti-anxiety medications. All patients were either treated for documented hypocalcemia or received prophylactic vitamin D and calcium supplements for the elevated risk of hypocalcemia in 22q11DS.\textsuperscript{7}: hippocampal atrophy; \textsuperscript{**}: focal scarring over right mid-temporal gyrus; O: psychosis not otherwise specified; 2° GTCs: secondarily generalized tonic-clonic seizures; ADHD: attention deficit hyperactivity disorder; ASD: autism spectrum disorder; BA: background activity; BF: bi-frontal; BPQ: both posterior quadrants; BT: bi-temporal; CPS: complex partial seizures; EEG: electroencephalogram; G: generalized; GAD: generalized anxiety disorder; G-PSW: generalized polyspike and waves; GTCs: generalized tonic-clonic seizures; HIMAL: hippocampal malrotation; IED: interictal epileptiform discharges; IS: intermittent slowing; LFC: left fronto-central; LFH: left frontal horn MD: major depression; MRI: magnetic resonance imaging; MS: myoclonic seizures; N: Normal; OCD: obsessive compulsive disorder; PMG: polymicrogyria; PNH: periventricular nodular heterotopia; RFH: right frontal horn; RT: right temporal; S: slow; SZ: schizophrenia, WM: white matter.
include the same AP level of the hippocampus on the same slice. In addition, isotropic sagittal high resolution T1 FSPGR sequences (1 mm thickness, isotropic voxels TE/TI/FA: (Min/450/12,1mm slice thickness, 256x256 Matrix)), and standard axial diffusion weighted and T2 * weighted gradient echo sequences were obtained.

Image analysis included careful evaluation of the mesial temporal lobe structures including evaluation of the hippocampal rotation. Hippocampal malrotation (HIMAL) was identified based on fulfilling all four Barsi criteria17: 1. unilateral involvement; 2. incomplete rotation of a hippocampus with abnormal round shape; 3. normal size and signal intensity; 4. blurred inner structure.

This study was approved by the University Health Network research ethics board.

RESULTS

Patients’ demographics and clinical characteristics are presented in the Table. Nineteen patients between 19-58 (average 30.5) years of age were assessed. Eight were females.

Seizures: Seven patients had a clinical history of recurrent, unprovoked, non-hypocalcemic seizures. EEG did not disclose any interictal epileptiform discharges (IEDs) in two of these patients. One patient had generalized, bisynchronous, 3-4 Hz frontally predominant polyspike and waves. Four patients had focal IEDs, indicating partial onset epilepsy. Of these four patients with focal IEDs, three had very poor

Figure 1: Hippocampal malrotation (HIMAL). 3T MRI of two coronal cuts (A and B) through the anterior third of the hippocampi. Note the right hippocampus (on the left side of the images) has an abnormal vertical orientation. All of the features in the strict characterization of HIMAL proposed by Barsi17 are also present: unilateral involvement, incomplete rotation of a hippocampus with abnormal round shape; normal size and signal intensity and blurred inner structure.

Figure 2: Prevalence of HIMAL in adult patients with 22q11.2 deletion syndrome from this study compared to the reported prevalence in studies of other conditions. Legend: Prevalence of HIMAL in the following populations: Control; this is represented here (first bar) as the mean of the values from three independent studies: 0/497 controls18, 5/5020 and 19/100 controls19. General Epilepsy Population: out of 527 patients with epilepsy (multiple causes) 32 (5%) had HIMAL17. Patients with Prolonged Febrile Seizures: out of 107 children enrolled, 12% of them had HIMAL21. Patients with Other Brain Developmental Abnormalities: The presence of HIMAL in patients with other hemispheric developmental disorders was 22%17. No genetic tests results were available in the above four categories of patients. Patients with Chromosome 22q11.2 Deletion: without screening for the presence of seizures 9 out of 14 had HIMAL. Patients with Chromosome 22q11.2 Deletion without Epilepsy: 6 out of 10 patients in this group had HIMAL. Patients with Chromosome 22q11.2 Deletion with epilepsy: 3 out of 4 patients in this group had HIMAL.
quality MRI and no correlation to structural abnormalities could be made. One patient with IEDs over both frontal and temporal regions had PNH over the left frontal horn and widespread PMG over the right hemisphere.

Structural abnormalities: Five patients moved or were claustrophobic during the MRI study. Therefore we had MRI of sufficient quality for 14 patients. Structural abnormalities that were previously described in patients with 22q11DS were seen in our group at the following rates: mild to moderate generalized atrophy in seven; PMG in one and PNH in three patients (the patient with PMG also had PNH). Focal scarring over the middle temporal gyrus in one patient. One patient had HA, without abnormal MRI signal, volume loss of the temporal white matter, or atrophy of the fornix or ipsilateral mammillary bodies to support the diagnosis of hippocampal sclerosis.

However, in addition to the abnormalities previously described in the literature, we found HIMAL in nine (64%) of the 14 patients with 22q11DS and good quality imaging (Figure 1). Of the three patients with malformations of cortical development (PMG and PNH), two also had HIMAL (66%). Of the 10 patients without epilepsy, six had HIMAL (60%). Of the four patients with epilepsy and good quality MRI, three had HIMAL (75%) (Figure 2).

Although this study was designed to look for causes of epilepsy in the 22q11DS population, we observed HIMAL in 50% of the patients with schizophrenia and 41% of those with mild or borderline intellectual disability.

**DISCUSSION**

Chromosome 22q11.2 microdeletion leads to a complex phenotype with several neurological problems. Different structural abnormalities have been described in this population: generalized brain atrophy,22 reduced volumes of parietal and temporal lobes,23 hippocampus,24 cerebellum and vermis,25 and thalami,26 as well as basal ganglia hypertrophy.27,28 Known structural changes that can be associated with seizures in this population include: HA,21 PMG,13 and PNH.44 However, the low prevalence of HA, PMG and PNH in 22q11DS is insufficient to explain why up to 7% of these patients have seizures. Interestingly our results revealed for the first time, that HIMAL, a potentially epileptogenic abnormality, three had HIMAL (75%) (Figure 2).

One patient with PMG also had PNH. Focal scarring over the middle temporal gyrus in one patient. One patient had HA, without abnormal MRI signal, volume loss of the temporal white matter, or atrophy of the fornix or ipsilateral mammillary bodies to support the diagnosis of hippocampal sclerosis.

HIMAL was observed in 75% of cases. These numbers suggest that the hemizygous deletion of the 22q11.2 region predisposes to HIMAL.

We propose that HIMAL results from the haploinsufficiency of one or more genes in the 22q11.2 microdeletion region. If this is true, why do all patients with 22q11DS not have HIMAL? The phenotypic variability that can result from a shared genetic abnormality may be explained by modulatory effects of other variants located elsewhere in the genome. Alternatively, the hemizygosity may unmask a recessive mutation in the other 22q11.2 allele. Other possibilities have also been proposed for phenotypic variability in 22q11DS.

Despite some statistical evidence of the association between HIMAL and epilepsy, the mechanism by which HIMAL leads to or is associated with epilepsy is not well understood. HIMAL is probably not the single reason leading to the development of seizures. However it can be a “first hit” that, in conjunction with other genetic or non-genetic factors may act in concert for the development or maintenance of seizures.29,30 HIMAL has also been associated with complex pre-frontal dysfunction in children with epilepsy31 and has been observed in adults with schizophrenia. Whether or not HIMAL is also associated with the other neuropsychiatric conditions seen in 22q11DS, e.g., intellectual disability, remains to be determined.

Temporal lobe and specifically hippocampal abnormalities have been previously described in patients with 22q11DS, however HIMAL has never been reported in this population. We believe the reason for this is that HIMAL is much better appreciated with the imaging protocol used in this study. This is a protocol designed for patients with temporal lobe epilepsy and therefore the coronal images on the 3 Tesla magnet allow better resolution and thus identification of this abnormality.

Limitations: The population studied here were from an adult 22q11DS cohort enriched for neuropsychiatric conditions. All these patients were initially seen in the psychiatry clinic and then referred to the epilepsy clinic. This may explain the higher prevalence of seizure disorders in our study compared to a large group of unselected younger patients with 22q11DS. Despite this, the prevalence of HIMAL observed was much higher than in patients with other forms of epilepsy or febrile seizures, both of which also represent pre-selected populations. It will be important to study a larger, randomly selected group of patients with 22q11DS with a similar MRI protocol to determine the overall prevalence of HIMAL. Another limitation is that this study was designed to determine the causes of seizures. Therefore the potential relationship between HIMAL and other neuropsychiatric abnormalities such as learning disabilities or schizophrenia will require further studies.
CONCLUSION

Hippocampal malrotation is overrepresented in patients with 22q11DS. Although HIMAL has been previously associated with seizures, its presence in 60% of 22q11DS patients without seizures (and 75% of those with seizures) suggest that other factors, as yet unknown, are also contributing to the increased epileptogenesis seen in this population. The role of HIMAL in the other neuropsychiatric abnormalities seen in this population will require further study.

ACKNOWLEDGEMENTS

DA received research grants from Physicians Services Incorporated and Ontario Brain Institute. Other grant support was received from the Canadian Institutes of Health Research (MOP-79518, MOP-89066, and MOP-97800) and Canada Research Chair in Schizophrenia Genetics and Genomic Disorders (ASB).

REFERENCES